drugset / Trial / NCT00003508

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

NCT00003508

Phase 2 Terminated 8 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Mesothelioma.

Timeline

Start
1996-03-08
Primary completion
2005-04-26
Completion
2005-04-26

Publications

  • Background Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in advanced malignant mesothelioma: A strategy for improved survival. Journal of Cancer Therapy. 2014; 5:1127-1144.
  • Background Burzynski SR, Lewy RI, Axler M, Janicki TJ.Treatment of malignant mesothelioma (MM) with sodium phenylbutyrate.Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous